#AANAM – MGTA-456 Cell Therapy Shows Promise in cALD Patients 6 Months After Transplant, Trial Update Shows
News
MGTA-456, Magenta Therapeutics’ candidate stem cell therapy, continues to show promise for stabilizing neurological function and resolving brain inflammation in patients with cerebral adrenoleukodystrophy (cALD), six-month follow-up data from two ... Read more